Serial 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)
- 1 February 2007
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 105 (1) , 87-94
Abstract
The response of bone-dominant (BD) breast cancer to therapy is difficult to assess by conventional imaging. Our preliminary studies have shown that quantitative serial 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG PET) correlates with therapeutic response of BD breast cancer, but the relationship to long-term outcome measures is unknown. Our goal was to evaluate the prognostic power of serial FDG PET in BD breast cancer patients undergoing treatment. We reviewed medical records of 405 consecutive breast cancer patients referred for FDG PET. Of these, 28 demonstrated metastatic BD breast cancer, were undergoing treatment, had at least 2 serial PET scans, and had abnormal FDG uptake on the first scan. Standardized uptake value (SUV) for the most conspicuous bone lesion at the initial scan, absolute change in SUV over an interval of 1–17 months, and percent change in SUV were considered as predictors of time-to-progression (TTP) and time to skeletal-related event (t-SRE). Using proportional hazards regression, smaller percentage decreases in SUV (or increases in SUV) were associated with a shorter TTP (P < 0.006). A patient with no change in SUV was twice as likely to progress compared to a patient with a 42% median decrease in SUV. A higher SUV on the initial FDG PET predicted a shorter t-SRE (hazard ratio = 1.30, P < 0.02). Changes in serial FDG PET may predict TTP in BD metastatic breast cancer patients. However, larger prospective trials are needed to validate changes in FDG PET as a surrogate endpoint for treatment response.Keywords
This publication has 16 references indexed in Scilit:
- Comparison of18FDG-PET with99mTc-HMDP scntigraphy for the detection of bone metastases in patients with breast cancerAnnals of Nuclear Medicine, 2005
- Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2005
- Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of boneEuropean Journal of Radiology, 2005
- Evolving role of positron emission tomography in breast cancer imagingSeminars in Nuclear Medicine, 2005
- Bone Imaging in Metastatic Breast CancerJournal of Clinical Oncology, 2004
- Current role of bone scan with phosphonates in the follow-up of breast cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2004
- Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions.Journal of Clinical Oncology, 1998
- MRI of bone metastasesEuropean Radiology, 1998
- Mechanisms of bone metastasisCancer, 1997
- Bone metastases: pathophysiology and management policy.Journal of Clinical Oncology, 1991